10/559899 IAP9 Rec'd PCT/PTO 06 DEC 2005

Docket No. VIP-0022-USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Van Marck et al.

Int'l Appln. No.: PCT/EP2004/051084

Serial No. : Unassigned Art Unit: Unassigned

Filed : I.A. 10.06.2004 Examiner: Unassigned

FOR : COMPUTATIONAL METHOD FOR PREDICTING THE

CONTRIBUTION OF MUTATIONS TO THE DRUG RESISTANCE PHENOTYPE EXHIBITED BY HIV BASED ON A LINEAR

REGRESSION ANALYSIS OF THE LOG FOLD RESISTANCE

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

$oxed{\boxtimes}$ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with the .
first or second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
- · · · · · · · · · · · · · · · · · · ·
In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
$oxed{\boxtimes}$ Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).
$oxedsymbol{oxed}$ There are no listed references which are not in the English language.
The relevance of those listed references which are
not in the English language is as follows:

. . .

•

10/559899 IAP9 Rec'd PCT/PTO 06 DEC 2005

\boxtimes	Attached	are co	pies d	of se	ear	ch rep	port	(s) from	n	
correspon	ding paten	t appl:	icatio	on(s)	٠,	which	are	listed	on	the
attached	Submission	Under	MPEP	609	D.					

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/VIP-0022-USPCT/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/

Laura A. Donnelly Reg. No. 38,435 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1729 DATED: December 6, 2005

10/559899 IAP9 Rec'd PCT/PTO 26 DEC 2005

	Application Number	Unassigned
	Filing Date	December 6, 2005
	First Named Inventor	Van Marck et al.
SUBMISSION UNDER MPEP 609 D	Group Art Unit	Unassigned
	Examiner Name	Unassigned
Page 1 of 1	Attorney Docket Number	VIP-0022-USPCT

		U.S. PA	TENT DOCUMENTS				
			U.S. Patent Document			Danes Column	a linna
Examiner Cite Initials No.1		Name of Patentee or Applicant of Cited Document			Kind Code where relev		ımns, Lines, nt passages oi ures appear
						. <u> </u>	
	1			<u> </u>			
	┼╌┤						
_	<u> </u>						
	1						
<u> </u>	· -						
	<u></u>	FOREIGN	PATENT DOCUMENTS				
Everniner	Cito	Name of Patentee or	Foreign Patent Document		where i	Columns, Lines, elevant passages elevant figures	т6

Examiner	Cite	Name of Patentee or	or relevant ligures		T ⁶		
Initials	No.1	Applicant of Cited Document	Office ³	Number⁴ Ki	ndCode ⁵	appear	
	,						
		OTHER PRIOR ART - N	ON PATENT	LITERATURE	DOCUMEN	ITS	
Examiner 's Initials*	Examiner Cite 's Cite No.¹ Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						T²
		International Search Report dated PCT/EP2004/051084.	June 28	, 2005 for	related Inte	ernational Application No.	
			-				
	<u> </u>						

Examiner	Date	•
	Considered	1
Signature	Considered	
Orginature_		

10/559899

IAP9 Rec'd PCT/PTO J 6 DEC 2009

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number	Unassigned
Filing Date	December 6, 2005
First Named Inventor	Van Marck et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	VIP-0022-USPCT

U.S. PATENT DOCUMENTS								
		1			Date of Publication	Pages, Columns, Lines,		
Examiner Initials	Cite No. ¹			Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear		
<u> </u>								
	<u> </u>							
	<u> </u>							
	<u> </u>				<u> </u>	-		
		<u></u>						

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Date of Publication Foreign Patent Document where relevant of Cited Document Name of Patentee or passages or relevant Cite mm-dd-yyyy Examiner Applicant of Cited Document figures appear Initials KindCode5 Number⁴ Office³ No.1 10-25-2001 WO 01/79540 A2 Virco N.V.

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

10/559899 [AP9 Rec'd PCT/PTO 06 DEC 2009]

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a valid OMB control number.						
Application Number	Unassigned					
Filing Date .	December 6, 2005					
First Named Inventor	Van Marck et al.					
Group Art Unit	Unassigned					
Examiner Name	Unassigned					
Attorney Docket Number	VIP-0022-USPCT					

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		Schmidt et al., "Simple algorithm derived from geno-/phenotypic database to predict HIV-1 protease inhibitor resistance", AIDS, Vol. 14, pp. 1731-1738 (2000).	
		Sevin et al., "Methods for Investigation of the Relationship between Drug-Susceptibility Phenotype and Human Immunodeficiency Virus Type 1 Genotype with Applications to AIDS Clinical Trials Group 333", The Journal of Infectious Diseases, Vol. 182, pp. 59-67 (2000).	
		Meisel et al., "Prediction of Metabolic Activity from Genotype: The Gene-Dose Effect of <i>N</i> -Acetyltransferase", Therapeutic Drug Monitoring, Vol. 23, pp. 9-14 (2001).	
		Beerenwinkel et al., "Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype", PNAS, Vol. 99, No. 12, pp. 8271-8276 (2002).	
		Beerenwinkel et al., "Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes", Nucleic Acid Research, Vol. 31, No. 13, pp. 3850-3855 (2003).	
		Schmidt et al., "Genotypic Drug Resistance Interpretation Systems – The Cutting Edge of Antiretroviral Therapy", AIDS, Vol. 4, pp148-156 (2002).	
-		Meisel et al., "Relationship between human genotype and phenotype of <i>N</i> -acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression: 1. Genotype and <i>N</i> -acetylation <i>in vivo</i> ", Vol. 7, pp. 241-246 (1997).	
	_		
		,	
 			

Examiner	Date	,
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.